

enough to reach a diagnostic threshold. This is partly due to the reactive nature of CMHT care and partly because of concerns about treating ‘false positives’, benign and transient states that will not make a transition into a major mental disorder. An unfortunate consequence of this well-meaning caution is that young people are denied earlier and safer interventions, which are not only clinically appropriate at an early stage, but have the potential for altering the prognosis and preventing the emergence of more serious illness.

A staging approach also offers exciting possibilities for developing specific clinical and biological markers of mental illnesses and understanding the relationship between clinical states and neuropathological and neurophysiological changes that accompany illness progression.<sup>3</sup>

I also share Dr Agius’ concern about the short-term financial pressures that may encourage managers to amalgamate early intervention services into CMHTs. This will simply dilute the well-established effectiveness of early intervention services in caring for vulnerable young people, while offering no improvement in CMHT functioning.

- 1 McGorry P, Purcell R, Hickie IB, Young AR, Pantelis C, Jackson HJ. Clinical staging: a heuristic model for psychiatry and youth mental health. *Med J Aust* 2007; **187**: 40–2.
- 2 Francey SM, Nelson B, Thompson A, Parker AG, Kerr M, Macneil C, et al. Who needs antipsychotic medication in the earliest stages of psychosis? A reconsideration of benefits, risks, neurobiology and ethics in the era of early intervention. *Schizophr Res* 2010; **119**: 1–10.
- 3 Fusar-Poli P, Howes OD, Allen P, Broome M, Valli I, Asselin M-C, et al. Abnormal frontostriatal interactions in people with prodromal signs of psychosis. A multimodal imaging study. *Arch Gen Psychiatry* 2010; **67**: 683–91.

**Swaran P. Singh**, Health Sciences Research Institute, Medical School Building, University of Warwick, Coventry CV4 7AL, UK. Email: S.P.Singh@warwick.ac.uk

doi: 10.1192/bjp.197.6.500a

## Dilemma over antipsychotic use in dementia

The editorial by Treloar *et al*<sup>1</sup> has raised a controversial but justified issue regarding antipsychotic prescription in patients with dementia. We agree with the editorial supporting the cautious use of these drugs based on the ethical premise of reducing patient distress and palliation. However, we felt that there was a relatively quick and unchallenged submission to another important premise of the observed harm, which is intricately related to the topic in question. Our strong concern is that such unequivocal acceptance of the observed risks is likely only to enhance the ethical dilemma in a reader’s mind. The decision to use these drugs, even for palliative purposes, is likely to be strongly governed by our safety and risk assessments. Are we not in a dilemma over the available safety evidence as well?

Is the observed harm specific to antipsychotic drugs, old age, dementia or behavioural and psychological symptoms of dementia (BPSD)? Is the observed association necessarily causation or are there certain limitations to a definite conclusion? For example, many a time the indication for which a drug is prescribed in dementia may be the cause of increased mortality rather than the drug *per se*. To quote the detailed Department of Health report,<sup>2</sup> ‘people with dementia and BPSD may be more likely to die (and to be prescribed antipsychotic drugs) than people with dementia and no BPSD’. Safety concerns regarding the use of antipsychotic drugs in elderly populations are a valid consideration, but are the risks also specifically higher for elderly people with dementia? The landmark meta-analysis of randomised controlled trials (RCTs),<sup>3</sup> which concluded with a small increased risk for

death with antipsychotics compared with placebo, also mentions that these results should be considered as hypothesis-generating. None of the individual drugs included in the 17 RCTs was sufficient to conclude for an increased risk, but a combined statistical effect was found. Does this call for a verification or should it be taken as conclusive?

Regarding efficacy studies, antipsychotic drugs have mostly been tested for treating BPSD. Behavioural and psychological symptoms of dementia is quite a heterogeneous term, used for an array of challenging behaviours such as restlessness, agitation, wandering, vocalisations, resisting help with dressing and personal hygiene, and verbal and physical aggression. Although the use of the term BPSD is quite appropriate in social dementia research (e.g. caregiver burden), is such a heterogeneous amalgamation of behaviours, which may or may not be of psychotic origin, a justified end-point to study clinical efficacy of drugs, or do we need more specific symptom clusters as indications of antipsychotic use in dementia? Further, is the number needed to treat (5–11) for antipsychotic drugs for behavioural improvement in dementia<sup>2</sup> any different from numbers needed to treat for antipsychotic drugs in schizophrenia?<sup>4</sup>

Undoubtedly, from a clinical perspective, extreme care and caution should be exercised in prescribing antipsychotics in old age, especially for those with an underlying organic illness (e.g. dementia). Regarding the dilemma whether they should ‘ever or never’ be prescribed for patients with dementia, our point of contention is: (a) we cannot focus the debate only on the ethical angle to resolve this dilemma, there are several unanswered medical questions; (b) we cannot close our eyes to the caveats in existing safety and efficacy studies; and (c) we need to resolve the ambiguity surrounding the available evidence to empower us for an ethical as well as informed decision. More than ever, the dilemma is to arrive at certain indications for which we can use antipsychotics with relative safety.

- 1 Treloar A, Crugel M, Prasanna A, Solomons L, Fox C, Paton C, et al. Ethical dilemmas: should antipsychotic ever be prescribed for people with dementia? *Br J Psychiatry* 2010; **197**: 88–90.
- 2 Banerjee S. *The Use of Antipsychotic Medication for People with Dementia: Time for Action*. Department of Health, 2009.
- 3 Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. *JAMA* 2005; **294**: 1934–43.
- 4 Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. *Cochrane Database Syst Rev* 2010; **1**: CD006918.

**Raman D. Pattanayak**, All India Institute of Medical Sciences, New Delhi, India. Email: draman@hotmail.com; **Sanjay K. Pattanayak**, All India Institute of Medical Sciences, New Delhi, India

doi: 10.1192/bjp.197.6.501

I agree with the views expressed by Treloar *et al*<sup>1</sup> regarding antipsychotic use in dementia. This is not only an ethical dilemma, but an issue of medical prescribing practice that has entered public and political domains. The present widespread use of antipsychotics seems to be unjustified but the emphasis should be on more rational use of these medications rather than an either/or debate. Our focus should be to develop policies and protocols which can lead to justified use of antipsychotics, with continuing reviews of the need for these medications. Their editorial is a step in right direction.

It seems that antipsychotic use in dementia is being demonised in the media.<sup>2–4</sup> Policy makers are also pushing for a decrease in their use. I have two issues with the direction this debate is taking us. First, I hope the pendulum does not swing